<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bio Nova International Pty Ltd</title>
	<atom:link href="http://www.bionova.com.au/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bionova.com.au</link>
	<description></description>
	<lastBuildDate>Wed, 15 Feb 2012 05:51:38 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Future medical treatment of endothelial dysfunction in diabetic patients</title>
		<link>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/future-medical-treatment-of-endothelial-dysfunction-in-diabetic-patients/1650/</link>
		<comments>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/future-medical-treatment-of-endothelial-dysfunction-in-diabetic-patients/1650/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 04:28:28 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Clinical Update]]></category>
		<category><![CDATA[Endothelial Dysfunction]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1650</guid>
		<description><![CDATA[Several therapeutic interventions have been tested in patients with diabetes and cardiovascular disease in an effort to improve endothelial function. These therapeutic interventions, in particular statin therapy, ACE inhibition, and arginine supplementation, have shown some improvements in these disease settings. Statins, which were initially designed as lipid-lowering drugs, demonstrate lipid-independent effects such as partially restoring [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/future-medical-treatment-of-endothelial-dysfunction-in-diabetic-patients/1650/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What are the underlying biological mechanisms of better patency with Omniflow II?</title>
		<link>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/what-are-the-underlying-biological-mechanisms-of-better-patency-with-omniflow-ii/1565/</link>
		<comments>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/what-are-the-underlying-biological-mechanisms-of-better-patency-with-omniflow-ii/1565/#comments</comments>
		<pubDate>Wed, 11 Jan 2012 04:40:45 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Clinical Update]]></category>
		<category><![CDATA[Endothelial Dysfunction]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1565</guid>
		<description><![CDATA[Published data have demonstrated the superior performance of OmniflowII (OFII) in terms of patency and resistance to infection. But what really is the underlying mechanism of the better performance of the biosynthetic graft? Today, we would like to focus on possible biological mechanisms of patency performance. It is important to emphasize that these are hypotheses [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/what-are-the-underlying-biological-mechanisms-of-better-patency-with-omniflow-ii/1565/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Brand positioning and sharpening communication on brand values and equity</title>
		<link>http://www.bionova.com.au/bionova-link/brand-positioning-and-sharpening-communication-on-brand-values-and-equity/1528/</link>
		<comments>http://www.bionova.com.au/bionova-link/brand-positioning-and-sharpening-communication-on-brand-values-and-equity/1528/#comments</comments>
		<pubDate>Sat, 31 Dec 2011 01:59:30 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Bionova Link]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1528</guid>
		<description><![CDATA[Our brand equity of better patency and resistance to infections has been amply justified with a cost benefit analysis based on fewer interventions for graft patency issues, lower infections and the more important decrease in the number of amputations in peripheral arterial disease and critical limb ischemia. The cost benefit advantage is also shown in [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/bionova-link/brand-positioning-and-sharpening-communication-on-brand-values-and-equity/1528/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Market Assessment</title>
		<link>http://www.bionova.com.au/bionova-link/market-assessment/1526/</link>
		<comments>http://www.bionova.com.au/bionova-link/market-assessment/1526/#comments</comments>
		<pubDate>Sat, 31 Dec 2011 01:57:37 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Bionova Link]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1526</guid>
		<description><![CDATA[We plan to assess product awareness and the attitude and usage of Omniflow II among key vascular surgeons in the markets where our flagship biosynthetic product Omniflow II has been approved for sale. Thanks to the help of some of you, we are beginning to understand the market and the brand value of Omniflow II [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/bionova-link/market-assessment/1526/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Connecting with Vascular Surgeons</title>
		<link>http://www.bionova.com.au/bionova-link/connecting-with-vascular-surgeons/1524/</link>
		<comments>http://www.bionova.com.au/bionova-link/connecting-with-vascular-surgeons/1524/#comments</comments>
		<pubDate>Sat, 31 Dec 2011 01:54:16 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Bionova Link]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1524</guid>
		<description><![CDATA[Our medical and product expertise allows us to better understand the unmet clinical needs that could be more effectively met by Omniflow II than competitive synthetic grafts. This insight can be translated into new revenue opportunities for us. It was through such interactions that we saw the emerging opportunity in AV access. More surgeons are [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/bionova-link/connecting-with-vascular-surgeons/1524/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Stents &#8211; bane or blessing?</title>
		<link>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/stents-bane-or-blessing/1461/</link>
		<comments>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/stents-bane-or-blessing/1461/#comments</comments>
		<pubDate>Wed, 21 Dec 2011 09:17:52 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Clinical Update]]></category>
		<category><![CDATA[Endothelial Dysfunction]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1461</guid>
		<description><![CDATA[It is interesting to observe the concern over the use of stent especially in coronary arteries especially for late re-stenosis. Much research has been conducted in understanding the molecular and genetic mechanisms involved in endothelial dysfunction caused by stent. We could learn the lessons from the coronary stent and apply them to the use of stent [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/stents-bane-or-blessing/1461/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Omniflow II for Dialysis Access features at German National Vascular Meeting</title>
		<link>http://www.bionova.com.au/1-news/omniflow-ii-for-dialysis-access-features-at-german-national-vascular-meeting/1453/</link>
		<comments>http://www.bionova.com.au/1-news/omniflow-ii-for-dialysis-access-features-at-german-national-vascular-meeting/1453/#comments</comments>
		<pubDate>Mon, 05 Dec 2011 10:44:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1453</guid>
		<description><![CDATA[The 2011 German National Vascular Surgery (DGG) congress in Erlangen, Germany in September featured the symposium “Biologische Gefäßimplantate in der Shuntchirurgie – neue Perspektiven” (“Biological Vascular Implants in Shunt Surgery – New Perspectives”). The focus was on Omniflow II in dialysis access, with speakers Mr Chemla from UK, Professor Palumbo from Italy and Dr Damirchi [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/1-news/omniflow-ii-for-dialysis-access-features-at-german-national-vascular-meeting/1453/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Endovascular procedures in dysfunctional dialysis access</title>
		<link>http://www.bionova.com.au/clinical-update/av-access/endovascular-procedures-in-dysfunctional-dialysis-access/1415/</link>
		<comments>http://www.bionova.com.au/clinical-update/av-access/endovascular-procedures-in-dysfunctional-dialysis-access/1415/#comments</comments>
		<pubDate>Thu, 17 Nov 2011 10:37:47 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[AV access]]></category>
		<category><![CDATA[Clinical Update]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1415</guid>
		<description><![CDATA[Thrombectomy, cutting and balloon angioplasty have been compared though not in randomised comparative studies in their effectiveness as intervention in dysfunctional dialysis access for AVF and AVG. There were promises with new methods such as cryoplasty and drug eluting balloon angioplasty but larger trials need to be conducted to validate early anecdotal success. Fistula failure-to-mature [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/av-access/endovascular-procedures-in-dysfunctional-dialysis-access/1415/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Challenges of the Central Vein Catheter</title>
		<link>http://www.bionova.com.au/clinical-update/av-access/challenges-of-the-central-vein-catheter/1410/</link>
		<comments>http://www.bionova.com.au/clinical-update/av-access/challenges-of-the-central-vein-catheter/1410/#comments</comments>
		<pubDate>Thu, 17 Nov 2011 10:30:53 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[AV access]]></category>
		<category><![CDATA[Clinical Update]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1410</guid>
		<description><![CDATA[From 1996 to 2007, in the wake of the ‘Fistula First’ campaign, arteriovenous fistula (AVF) use in the US nearly doubled from 24 to 47%, while over the same time period use of AV grafts (AVGs) declined from 58 to 27%. During the same time, use of central vein catheters increased from 18 to 26%. [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/av-access/challenges-of-the-central-vein-catheter/1410/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Endothelial Dysfunction in Vascular disease</title>
		<link>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/endothelial-dysfunction-in-vascular-disease/1383/</link>
		<comments>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/endothelial-dysfunction-in-vascular-disease/1383/#comments</comments>
		<pubDate>Thu, 17 Nov 2011 08:22:50 +0000</pubDate>
		<dc:creator>Dr Stephen Phua</dc:creator>
				<category><![CDATA[Clinical Update]]></category>
		<category><![CDATA[Endothelial Dysfunction]]></category>

		<guid isPermaLink="false">http://www.bionova.com.au/?p=1383</guid>
		<description><![CDATA[The ideal vascular graft should incorporate human endothelium in its intimal surface as research is beginning to unfold the importance of endothelium in vascular performance. The holy grail in the management of peripheral vascular disease or for that matter cardiovascular disease associated particularly with diabetes is in the understanding of endothelial dysfunction. Current research on [...]]]></description>
		<wfw:commentRss>http://www.bionova.com.au/clinical-update/endothelial-dysfunction/endothelial-dysfunction-in-vascular-disease/1383/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

